CoQ10observational2003

Hybrid ubiquinone: novel inhibitor of mitochondrial complex I.

Biochimica et biophysica acta

confidence

Key findings

Hybrid ubiquinones act as substrates for complex II/III but noncompetitive inhibitors of complex I; phenoxybenzamide moiety drives inhibition.

View source on PubMed (PMID 12460667) ↗

Sample size
N/A
Population
In vitro bovine heart mitochondria (biochemical assay)
Dosing
N/A
Duration
N/A
Route
in vitro
Blinding
not_reported
Controls
none
Drug class
mitochondrial cofactor
Full abstract

We synthesized novel ubiquinone analogs by hybridizing the natural ubiquinone ring (2,3-dimethoxy-5-methyl-1,4-benzoquinone) and hydrophobic phenoxybenzamide unit, and named them hybrid ubiquinones (HUs). The HUs worked as electron transfer substrates with bovine heart mitochondrial succinate-ubiquinone oxidoreductase (complex II) and ubiquinol-cytochrome c oxidoreductase (complex III), but not with NADH-ubiquinone oxidoreductase (complex I). With complex I, they acted as inhibitors in a noncompetitive manner against exogenous short-chain ubiquinones irrespective of the presence of the natural ubiquinone ring. Elongation of the distance between the ubiquinone ring and the phenoxybenzamide unit did not recover the electron accepting activity. The structure/activity study showed that high structural specificity of the phenoxybenzamide moiety is required to act as a potent inhibitor of complex I. These findings indicate that binding of the HUs to complex I is mainly decided by some specific interaction of the phenoxybenzamide moiety with the enzyme. It is of interest that an analogous bulky and hydrophobic substructure can be commonly found in recently registered synthetic pesticides the action site of which is mitochondrial complex I.

Research information, not medical advice. StudyKit summarizes published studies to help you understand your protocol. It does not diagnose, treat, or replace a clinician. Talk to a qualified provider before changing anything you take.